gms | German Medical Science

GMS Ophthalmology Cases – An Open Access Journal

Bundesverband Deutscher OphthalmoChirurgen e. V. (BDOC)

ISSN 2193-1496

Sequential development of non-arteritic anterior ischemic optic neuropathy in a patient on hemodialysis

Case Report

Suche in Medline nach

  • author Mukesh Jain - Department of Ophthalmology, JIPMER, Dhanvantri Nagar, Gorimedu, Puducherry, India
  • author Renuka Srinivasan - Department of Ophthalmology, JIPMER, Dhanvantri Nagar, Gorimedu, Puducherry, India
  • author K. Ramesh Babu - Department of Ophthalmology, JIPMER, Dhanvantri Nagar, Gorimedu, Puducherry, India
  • corresponding author M. Swapnil Parchand - Department of Ophthalmology, JIPMER, Dhanvantri Nagar, Gorimedu, Puducherry, India

GMS Ophthalmol Cases 2017;7:Doc22

doi: 10.3205/oc000073, urn:nbn:de:0183-oc0000734

Veröffentlicht: 1. September 2017

© 2017 Jain et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe


Purpose: Non-arteritic anterior ischemic optic neuropathy (NA-AION) is typically a disorder of patients 50 years and older predisposed to the vascular and structural optic disc risk factors. We present an interesting case of sequential development of NA-AION in a 45-year-old patient with end-stage renal disease undergoing hemodialysis.

Methods: Observational case report.

Results: A 45-year-old female on hemodialysis for chronic renal failure complained of sequential acute onset sudden painless gross diminution of vision in right eye followed by the left eye. At presentation, fundus examination revealed secondary optic atrophy and a pallid disc edema with few hemorrhage in the right and left eye, respectively. Ambulatory blood pressure recorded nocturnal dips of diastolic blood pressure. Fundus fluorescein angiography showed hypoperfusion of the left optic disc, confirming the diagnosis of NA-AION. She was treated with oral steroids, but with no improvement.

Conclusion: Both treating nephrologist and ophthalmologist should be aware of this uncommon but potentially blinding complication, to permit its early recognition and prevent the occurrence in the fellow eye. Also, care should be taken to prevent and treat any hypotensive episodes during and following dialysis therapy in such high-risk patients.


Non-arteritic anterior ischemic optic neuropathy (NA-AION) is the most common cause of acute optic neuropathy in older age. It is caused due to circulatory insufficiency within the optic nerve head [1], [2] The common predisposing factors associated with NA-AION are systemic hypertension, diabetes, and hypercholesterolemia. A small crowded disc is seen in a majority of patients with NA-AION. The relatively inflexible lamina cribrosa provides the setting for a compartment syndrome within the optic nerve head, resulting in a vicious cycle of ischemia and compression. According to Newman et al., the chance of the fellow eye being involved is 15% at five years [3]. It is rarely seen in patients below 50 years of age. Few case reports have documented occurrence of NA-AION in individuals below 50 years of age with hyperhomocysteinemia, thrombophilia (lupus anticoagulants, anticardiolipin antibodies, prothrombotic polymorphisms (factor V Leiden), and deficiencies of protein C, S, and antithrombin III), severe haemorrhage with secondary hypotension, anemia and in patients on dialysis for chronic renal failure [4], [5], [6], [7]. Arnold et al. showed that the fellow eye involvement rate was significantly higher in young patients compared to the elderly; 42.6% versus 29.6% [6]. We report a rare case of sequential development of NA-AION in a patient with end-stage renal disease undergoing hemodialysis.

Case description

A 45-year-old female complained of gross diminution of vision in the left eye (LE) on awakening 20 days before. She had a similar history of sudden onset painless diminution of vision in the right eye (RE) two months before. She had diabetes, hypertension, and anemia with chronic kidney disease. She was on hemodialysis bi-weekly for the last 3 years. She gave a history of dialysis a day prior to both of the episodes of acute visual loss. She had no history of headache, pain on extra-ocular movements, limb-weakness, transient ischemic attacks, fever, myalgia, jaw claudication, seizures or focal neurological deficit.

On examination, best-corrected visual acuity (BCVA) was 6/60 in RE and hand movements close to face (HMCF) with accurate projection of rays in LE. Intraocular pressure was 14 and 15 mm of Hg in RE and LE, respectively. LE had grade 1 relative afferent pupillary defect (RAPD). Anterior segment examination of both eyes (BE) was normal. Fundus examination in RE showed optic disc pallor with obliteration of cup and sheathing of vessels around the disc suggesting secondary optic atrophy (Figure 1A [Fig. 1]) with arteriolar attenuation and arterio-venous (A-V) crossing changes. Fundus examination of LE showed pallid disc edema with flame-shaped retinal haemorrhages in the peri-papillary region, attenuation of the retinal arterioles, and arterio-venous crossing changes without any background diabetic retinopathy (Figure 1B [Fig. 1]).

Humphery’s visual field testing in RE showed severely depressed field. Field examination in LE was not possible due to profound visual loss. Fundus fluorescein angiography (FFA) of LE showed delayed filling of the disc especially superior part in the early phase and staining of disc in the late phase (Figure 2 [Fig. 2]).

Her blood pressure was 110/80 mmHg. Ambulatory blood pressure monitoring showed a drop in nocturnal blood pressure with diastolic reading dipping to 55 mmHg. There was no evidence of any neurological deficit. Her haemoglobin level was 9.5 g/dl. Her blood urea was 78 mg/dl and serum creatinine was 6.2 mg/dl. Serum electrolytes and other routine biochemical tests were within the normal range. Contrast enhanced computer tomography of the head revealed normal study.

Based on the above findings, she was diagnosed as having secondary optic atrophy following NA-AION in RE and fresh NA-AION in LE. She was started on oral steroid 80 mg/day with close monitoring of blood sugar levels and blood pressure. Steroids were tapered over 8 weeks. Despite these measures, there was no improvement of vision in LE. At last follow-up at 6 months, best corrected visual acuity was 6/60 in RE and HMCF in LE with BE showing secondary optic atrophy.


NA-AION is a disease of the elderly presenting typically with sudden onset painless diminution of vision, mostly reported on awakening [1], [2]. Clinical features include RAPD and disc edema. Optic Disc edema can be diffuse or segmental. Most common documented visual field defect in NA-AION is the altitudinal defect [2]. But in many of these cases, visual field may be severely depressed or non-recordable [8]. FFA helps to confirm the diagnosis by demonstrating delayed disc filling suggestive of hypo-perfusion and resulting ischemia. Insufficiency of optic disc circulation exacerbated by structural crowding of nerve fibers and supporting structures at the nerve head leads to inadequate oxygenation and ultimately ischemia and swelling of the disc. Also, a vicious cycle of ischemia, axonal swelling, microvascular compression, and further ischemia may lead to progressive nerve damage. Such progressive form is reported in 37% of NA-AION cases [9]. Nocturnal hypotension is the most important risk factor for development of NA-AION. Hence, most of the patients complain of visual loss on awakening [2].

Recurrent hypotensive episodes seen in an individual on dialysis for end-stage renal disease are another important risk factor for development of NA-AION [6], [7]. The incidence of symptomatic reduction in blood pressure during or immediately following dialysis ranges from 15–50% of dialysis sessions. Ghaffar et al. reported 9% of dialysis patient experience a decrease in their systolic blood pressure to below 80 mmHg during dialysis [10]. These individuals are often young with hypertension related vascular changes and also have anemia. These compounded with the frequent hypotensive episodes during dialysis makes them highly vulnerable to NA-AION, which at times may be bilateral or sequential [11], [12], [13], [14]. Our case had chronic hypertension, anemia, and end-stage renal disease requiring hemodialysis for 3 years. Occurrence of episodes of sudden loss of vision on awakening in LE a day after dialysis, pallid disc edema, delayed filling of disc in LE on FFA, no other ocular or neurologic disorder that could be responsible for disc edema, visual loss, and ambulatory blood pressure dipping to 55 mmHg confirmed the diagnosis of NA-AION secondary to hypotensive episode following hemodialysis in above patient.

Dialysis related hypotension has a complex pathogenesis that includes insufficient vascular filling, dysfunction of the autonomous nervous system, alteration of the global diastolic ventricular function, imbalance in the vasoactive agents concentration, and feeding during the dialysis [15]. The insufficient vascular filling is caused due to depletion of volume of the interstitial space mainly by an overestimation of dry weight, low plasma osmolality with the use of low sodium concentration dialysate, decrease oncotic pressure of the capillary space or severe anemia. Dysfunction of the autonomic nervous system is due to downregulation of the adrenergic receptors. Hence, there is suboptimal compensatory cardiac and peripheral vascular resistance response to volume depletion induced by ultrafiltration. Based on these observations, it is recommended that ultrafiltration profiling, sodium-cold dialysate, and weight-based ultrafiltration are some of the measures to decrease the episodes of hypotension.

Another close differential diagnosis in patients with renal disease is uremic optic neuropathy. It is a rare entity that primarily affects individuals having highly deranged renal parameters [16]. Generally, it affects individuals with undiagnosed renal failure. Patients on maintenance dialysis are rarely affected. Visual impairment in this condition is due to direct toxic effect of dialyzable metabolites. Chronic exposure to these metabolites can lead to irreversible damage. Hence, such patients should undergo early and prompt dialysis. Knox reported significant improvement in five of six patients who underwent prompt treatment with hemodialysis and steroids [8]. Our patient was already on hemodialysis and had blood urea and serum creatinine within reasonable limits ruling out this possibility.

There is no proven therapy for NA-AION. Steroids have often being used in literature with a rationale that steroids if given during very early stages of the disease might reduce capillary permeability, leading to quicker resolution of disc edema [17]. Our patient received a course of systemic steroid but did not show any visual improvement probably because of delayed presentation. Ischemic optic neuropathy decompression trial also did not reveal any significant benefit of optic nerve decompression in NA-AION [18], [19]. A controlled clinical study of the effect of hyperbaric oxygen in NA-AION did not show any benefit with this treatment either [20]. Hence, once NA-AION is established, no treatment is effective in restoring the vision. Therefore, all care should be taken to prevent episodes of hypotension during and after dialysis. Also, single blood pressure reading may not identify patients at risk. Hence, a 24-hour ambulatory blood pressure monitoring may be done in such patients to identify early morning hypotension.


Dialysis related hypotension is an important risk factor for development of NA-AION that may be recurrent or sequential. Both treating nephrologist and ophthalmologist should be aware of this potentially blinding complication. Twenty-four hour ambulatory blood pressure monitoring should be done to identify patients at risk. Care should be taken to prevent hypotensive episodes during and after dialysis.


Competing interests

The authors declare that they have no competing interests.


We would like to thank Dr. Nirupama Kasturi, Asst. Professor, Department of Ophthalmology, JIPMER for her support.


Hayreh SS, Podhajsky P, Zimmerman MB. Role of nocturnal arterial hypotension in optic nerve head ischemic disorders. Ophthalmologica. 1999;213(2):76-96. DOI: 10.1159/000027399 Externer Link
Hayreh SS. Ischaemic optic neuropathy. Indian J Ophthalmol. 2000 Sep;48(3):171-94.
Newman NJ, Scherer R, Langenberg P, Kelman S, Feldon S, Kaufman D, Dickersin K; Ischemic Optic Neuropathy Decompression Trial Research Group. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol. 2002 Sep;134(3):317-28. DOI: 10.1016/S0002-9394(02)01639-2 Externer Link
Kuhli-Hattenbach C, Scharrer I, Lüchtenberg M, Hattenbach LO. Thrombophile Gerinnungsstörungen bei unter 60-jährigen Patienten mit nichtarteriitischer anteriorer ischämischer Optikusneuropathie [Thrombophilic disorders associated with non-arteritic anterior ischaemic optic neuropathy in patients <60 years of age]. Klin Monbl Augenheilkd. 2008 Dec;225(12):1065-9. DOI: 10.1055/s-2008-1027488 Externer Link
Onaran Z, Tan FU, Yılmazbaş P, Onaran Y. Bilateral non-arteritic anterior ischemic optic neuropathy following second-trimester spontaneous abortion-related haemorrhage. J Clin Neurosci. 2012 Oct;19(10):1445-7. DOI: 10.1016/j.jocn.2011.11.033 Externer Link
Arnold AC, Costa RM, Dumitrascu OM. The spectrum of optic disc ischemia in patients younger than 50 years (an Amercian Ophthalmological Society thesis). Trans Am Ophthalmol Soc. 2013 Sep;111:93-118.
Nieto J, Zapata MA. Bilateral anterior ischemic optic neuropathy in patients on dialysis: A report of two cases. Indian J Nephrol. 2010 Jan;20(1):48-50. DOI: 10.4103/0971-4065.62094 Externer Link
WuDunn D, Zimmerman K, Sadun AA, Feldon SE. Comparison of visual function in fellow eyes after bilateral nonarteritic anterior ischemic optic neuropathy. Ophthalmology. 1997 Jan;104(1):104-11. DOI: 10.1016/S0161-6420(97)30354-6 Externer Link
Yee RD, Selky AK, Purvin VA. Outcomes of optic nerve sheath decompression for nonarteritic ischemic optic neuropathy. J Neuroophthalmol. 1994 Jun;14(2):70-6. DOI: 10.1097/00041327-199406000-00003 Externer Link
Ghaffar U, Easom AK. A quality improvement project: Strategies to reduce intradialytic hypotension in hemodialysis patients. Nephrol News Issues. 2015 May;29(5):30, 32, 34 passim.
Korzets A, Marashek I, Schwartz A, Rosenblatt I, Herman M, Ori Y. Ischemic optic neuropathy in dialyzed patients: a previously unrecognized manifestation of calcific uremic arteriolopathy. Am J Kidney Dis. 2004 Dec;44(6):e93-7.
Servilla KS, Groggel GC. Anterior ischemic optic neuropathy as a complication of hemodialysis. Am J Kidney Dis. 1986 Jul;8(1):61-3. DOI: 10.1016/S0272-6386(86)80156-1 Externer Link
Jackson TL, Farmer CK, Kingswood C, Vickers S. Hypotensive ischemic optic neuropathy and peritoneal dialysis. Am J Ophthalmol. 1999 Jul;128(1):109-11. DOI: 10.1016/S0002-9394(99)00026-4 Externer Link
Buono LM, Foroozan R, Savino PJ, Danesh-Meyer HV, Stanescu D. Posterior ischemic optic neuropathy after hemodialysis. Ophthalmology. 2003 Jun;110(6):1216-8. DOI: 10.1016/S0161-6420(03)00257-4 Externer Link
Rezki H, Salam N, Addou K, Medkouri G, Benghanem MG, Ramdani B. Comparison of prevention methods of intradialytic hypotension. Saudi J Kidney Dis Transpl. 2007 Sep;18(3):361-4.
Knox DL, Hanneken AM, Hollows FC, Miller NR, Schick HL Jr, Gonzales WL. Uremic optic neuropathy. Arch Ophthalmol. 1988 Jan;106(1):50-4. DOI: 10.1001/archopht.1988.01060130056027 Externer Link
Hayreh SS, Zimmerman MB. Non-arteritic anterior ischemic optic neuropathy: role of systemic corticosteroid therapy. Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):1029-46. DOI: 10.1007/s00417-008-0805-8 Externer Link
Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group. JAMA. 1995 Feb 22;273(8):625-32. DOI: 10.1001/jama.1995.03520320035038 Externer Link
Ischemic Optic Neuropathy Decompression Trial: twenty-four-month update. Arch Ophthalmol. 2000 Jun;118(6):793-8. DOI: 10.1001/archopht.118.6.793 Externer Link
Arnold AC, Hepler RS, Lieber M, Alexander JM. Hyperbaric oxygen therapy for nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1996 Oct;122(4):535-41. DOI: 10.1016/S0002-9394(14)72114-2 Externer Link